Search Site

Cory T. Abate-Shen, PhD

  • Michael and Stella Chernow Professor of Urologic Sciences (in Urology)
  • Professor of Pathology and Cell Biology (in the Herbert Irving Comprehensive Cancer Center)
Cory T. Abate-Shen, PhD

Cory Abate-Shen, Ph.D., joined the faculty of Columbia University Medical Center and the Herbert Irving Comprehensive Cancer Center in 2007. A leader in the field of urological oncology, Dr. Abate-Shen is the Michael and Stella Chernow Professor of Urologic Sciences, director of research in the Department of Urology, and an associate director of HICCC and leader of its Prostate Program.

Dr. Abate-Shen obtained her Ph.D. at Cornell University Medical College, and pursued her postdoctoral training with Tom Curran at the Roche Institute of Molecular Biology. In 1991, she joined the University of Medicine & Dentistry of New Jersey-Robert Wood Johnson Medical School as an assistant professor. She rose to the rank of professor by 2001, and was appointed chief of a new Division in the Department of Medicine in 2002. Dr. Abate-Shen also created the Prostate Program for the Cancer Institute of New Jersey and served as its co-leader from 1999 to 2007. 

Among her various honors and awards, she has recently been selected as an American Cancer Society Research Professor, the first ever at Columbia University Medical School.

Email: ca2319@cumc.columbia.edu

Dr. Abate-Shen’s research focuses on the molecular mechanisms of cancer development. She has a longstanding commitment to the generation of mouse models of cancer and their effective use for translational research. Her major research interests are in the area of genitourological cancer. Most notably, her laboratory has developed novel models of prostate and bladder cancer, which have been utilized for investigating the molecular basis of the disease as well as preclinical models for evaluating new therapies.

Research Interests

  • Molecular mechanisms of cancer development
  • Genitourinary cancer development

NIH Grants

  • MOLECULAR DETERMINANTS OF PROSTATE CANCER PROGRESSION (Private)

    Jan 1 2016 - Dec 31 2021

    CENTERS FOR CANCER SYSTEMS THERAPEUTICS (CAST) (Federal Gov)

    Aug 8 2016 - Jul 31 2021

    INVESTIGATING THE CELL OF ORIGIN OF BLADDER CANCER (Federal Gov)

    Apr 1 2015 - Mar 31 2020

    MOLECULAR MECHANISMS OF PROSTATE CANCER METASTASIS (Federal Gov)

    Jan 1 2015 - Dec 31 2019

    ANALYSIS OF DRUG RESPONSE IN ORGANOIDS AND MOUSE MODELS (Federal Gov)

    Jul 1 2016 - Jun 30 2019

    CANCER CENTER SUPPORT GRANT (Federal Gov)

    Jul 1 2014 - Jun 30 2019

    CHARACTERIZATION OF EPIGENETIC REGULATORY DRIVERS OF PROSTATE CANCER METASTASIS (Federal Gov)

    Sep 15 2016 - Sep 14 2018

    PRECLINICAL ANALYSES OF ADVANCED PROSTATE CANCER IN GENETICALLY-ENGINEERED MICE (Federal Gov)

    Aug 6 2013 - May 31 2018

    FUNCTIONAL IDENTIFICATION OF MASTER REGULATORS OF PROSTATE CANCER METASTASIS THROUGH CRISPR/CAS9 SCREENING (Federal Gov)

    Jul 1 2015 - Aug 16 2017

    EPIGENETIC REGULATION OF BLADDER CANCER PROGRESSION (Private)

    Jul 15 2015 - Jul 14 2017

    RESEARCH FOR A 5-GENE PANEL (PRO-SCOPE) FOR IMPROVED EARLY DIAGNOSIS OF PROSTATE CANCER (Private)

    Mar 6 2015 - Mar 5 2017

    MOLECULAR MECHANISMS OF PROSTATE CANCER INITIATION (Federal Gov)

    Sep 16 2011 - Feb 28 2017

    MOLECULAR DETERMINANTS OF PROSTATE CANCER PROGRESSION (Private)

    Jan 1 2012 - Dec 16 2016

    CHARACTERIZATION OF EPIGENETIC REGULATORY DRIVERS OF PROSTATE CANCER METASTASIS (Private)

    Nov 1 2015 - Sep 14 2016

    NATIONAL CENTER: MULTISCALE ANALYSIS OF GENOMIC AND CELLULAR NETWORKS (MAGNET) (Federal Gov)

    Sep 26 2005 - Jul 31 2016

    CELL OF ORIGIN OF BLADDER CANCER (Private)

    Jul 1 2014 - Jun 30 2016

    THE T.J. MARTELL FOUNDATION FOR LEUKEMIA, CANCER AND AIDS RESEARCH (Private)

    Jan 1 2015 - Dec 31 2015

    LEADERSHIP COMPONENT IN CHEMOPREVENTION: MOUSE MODELS OF HUMAN CANCER CONSORTIUM (Federal Gov)

    Sep 1 2009 - Aug 31 2015

    ELUCIDATION OF CANCER PATHWAYS AND DRUGGABLE TARGETS USING MOUSE MODELS (Federal Gov)

    Sep 30 1999 - Jul 31 2015

    ANALYSES OF THE ROLE OF P53 IN ABIRATERONE RESPONSE (Private)

    Jul 1 2014 - Nov 14 2014

    PRECLINICAL INVESTIGATIONS OF FINASTERIDE IN MOUSE MODELS OF PROSTATE CANCER (Federal Gov)

    Jul 1 2012 - May 31 2014

    PRE-CLINICAL AND CLINICAL APPROACHES FOR DEVELOPING NEW TREATMENTS FOR CASTRATION-RESISTANT PROSTATE CANCER (Private)

    Sep 1 2010 - Aug 31 2013

    ASSEMBLY OF A PROSTATE CANCER GENOME-WIDE MOLECULAR INTERACT OME FOR THE IDENTIFICATION OF THE KEY REGULATORY GENES OF MA (Private)

    Aug 1 2010 - Jul 31 2013

    THE USE OF INTRAVESICAL CABAZITAXEL, GEMCITABINE, AND CISPLA TIN (CGC) IN THE TREATMENT OF HIGH RISK NON-MUSCLE INVASIVE (Private)

    Jul 1 2012 - Jun 30 2013

    MOLECULAR MECHANISMS OF INVASIVE BLADDER CANCER: ANALYSIS OF ARF FUNCTION IN P53/PTEN (Private)

    Jul 1 2011 - Jun 30 2012

    NOVEL THERAPEUTIC TARGETS IN INVASIVE BLADDER CANCER (Private)

    Jul 1 2011 - Jun 30 2012

    MODELING ANDROGEN-INDEPENDENT PROSTATE CANCER IN MUTANT MICE (Federal Gov)

    Apr 1 2007 - Jan 31 2012

    ANALYSES OF EARLY STAGE PROSTATE CARCINOGENESIS: TARGETING T HE NFKB PATHWAY FOR EARLY INTERVENTION (Private)

    Jul 1 2009 - Jun 30 2011

    NEXT-GENERATION MOUSE MODELS OF PROSTATE CANCER PROGRESSION AND METASTASES (Private)

    Jul 1 2008 - Jun 30 2011

    PRECLINICAL TESTING OF MTOR AND AKT INHIBITORS ON A MOUSE MO DEL OF PROSTATE CANCER (Private)

    Jun 24 2009 - Jun 23 2011

    PRECLINICAL STUDIES OF SIGNALING PATHWAY IN A MUTANT MOUSE M ODEL OF HORMONE-REFRACTORY PROSTATE CANC (Federal Gov)

    Jan 28 2008 - Apr 30 2011

    ROLE FOR MSX1 IN VERTEBRATE EMBRYOGENSIS (Federal Gov)

    Aug 1 1992 - Nov 30 2009

    CHEMOPREVENTION OF PROSTATE CANCER IN MUTANT MICE: TARGETING THE ANDROGEN RECEPTOR SIGNALING PATHWAY (Federal Gov)

    Dec 2 2007 - Nov 14 2009

Lab Projects